WeWork is a symptom of a disease that may not have a cure

The spectacular blow-up of the public offering of WeWork’s parent company We Co. shows that the public markets are savvier than private investors about buying into the hype of high-value, high-risk unicorn companies masquerading as tech companies. But will anything change in the new world where companies wait as long as possible to go public?